Medical Developments International Limited · ASX:MVP
Medical Developments International — Investor Presentation (March 2017)
55 slides from Medical Developments International's investor presentation, Mar 3, 2017
Slide 1: Medical Developments International Road Show
For personal use only Medical Developments International Road Show
Slide 2: Disclaimer
Disclaimer This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, For personal use only ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discu
Slide 3: Vision
Vision For personal use only Medical Developments International (MDI) is a leading Emergency Medicine Company. Our aim is to: 1. Provide unique and innovative products to assist our customers in the management of acute pain, trauma and procedural pain and to be the market leader in these markets glo
Slide 4: The Business
The Business For personal use only MDI is delivering two world class “company making” business opportunities. The risk profile of these opportunities is relatively low and well understood. Penthrox: Penthrox has the potential to be the market leader in acute pain markets around the world. Penthrox i
Slide 5: Key achievements of H1FY17
For personal use only Key achievements of H1FY17 5
Slide 6: Key achievements of H1FY17: Penthrox
Key achievements of H1FY17 Penthrox® For personal use only • First sales of Penthrox® in France and Belgium • National reimbursement of Penthrox® in France • Submitted Regulatory Applications to have Penthrox® approved in 22 countries • Regulatory approval in the UAE • Regulatory approval in Taiwan
Slide 7: Key achievements of H1FY17: Respiratory Medical Devices
Key achievements of H1FY17 Respiratory Medical Devices For personal use only • Global sales growth of 142% • Signed new distribution deal in USA with McKesson • Sales growth of 148% for USA • First sales into 1,600 pharmacies in the USA. More to follow • Sales growth of 192% in Australia • Record sa
Slide 8: Key achievements of H1FY17: Corporate
Key achievements of H1FY17 Corporate For personal use only • $5.5 million cash in bank • No debt • Construction of new manufacturing facility on time and on budget. Due for completion in March 2017 • Continued investment in new product development • PDCO approval of Paediatric Study protocol, first
Slide 9: Introducing Penthrox
For personal use only Introducing Penthrox 9
Slide 10: Penthrox: A world class opportunity
Penthrox® A world class opportunity For personal use only Penthrox® • Market Leader for trauma pain • Opiate sparing, fast acting inhalational analgesic 1 • 85% of patients reach clinical analgesia within 10 breaths • Is a solution to a significant unmet clinical need • Demonstrated safety and effic
Slide 11: Penthrox: A world class opportunity
Penthrox A world class opportunity For personal use only Penthrox® • Sold in 17 countries around the world including Australia, UK, France, Ireland , South Africa, Singapore, Belgium, New Zealand, UAE, Qatar and elsewhere. • Major distribution deals signed in Europe and elsewhere in 2015. • $18.5 mi
Slide 12: Penthrox history and planned launches
Penthrox® History and planned launches 2010 For personal use only Pre 2000 2015 2020 2021 - 2022 Planned 2019- 2020 Launch: Malaysia Planned 2017 & 2018 Thailand Launch: Philippians Planned Launch: Brazil 2016 Canada Indonesia Columbia 2014 Launched: Germany Chile Launched: Irela
Slide 13: Penthrox clinical application
Penthrox® Clinical application For personal use only Painful procedures Painful procedures • Burn injuries • Cutaneous excisions Cosmetic Dentistry Surgery • Liquid nitrogen removals of • Breaks, fractures and skin-cancers, warts, etc. dislocations Military Consulting • Invasive angiographies Rooms
Slide 14: Benefits to medical professionals
Penthrox Benefits to medical professionals For personal use only Rapid onset Minimal waiting time before a painful procedure can be performed (3 minutes) and of action rapid pain relief when a patient is treated for acute pain, trauma, and minor surgical procedures. Inhaled Medical professionals can
Slide 15: Benefits over Opiates
Penthrox Benefits over Opiates For personal use only The benefits of using Penthrox® over Morphine include: • Penthrox does not effect vital signs; no clinical depression of respiration or circulation. • Penthrox can be used on children, Morphine often cannot. • Penthrox is not a narcotic, nor is it
Slide 16: Benefits over Nitrous Oxide
Penthrox Benefits over Nitrous Oxide For personal use only The benefits of using Penthrox® over Nitrous Oxide include: • Penthrox does not effect vital signs; no clinical depression of respiration or circulation. • Penthrox is self-administered and easy to use. • Penthrox is compact and can be used
Slide 17: Non-narcotic and clinically proven efficacy
Penthrox Non-narcotic and clinically proven efficacy For personal use only VAS scores compared, IV morphine vs IN fentanyl vs Penthrox Summary of mean VAS Pain Scores The criteria for the cross study comparison were a similar study design Time 0 5 minutes 10 minutes 15 minutes 20 minutes 30 minutes
Slide 18: Provides rapid pain relief
Penthrox® Provides rapid pain relief For personal use only Average pain reduction from point of adminstration1-2 Time (minutes) 0 0 5 10 15 20 30 -5 Morphine Adjusted change from baseline (mm) Fentanyl Visual Analogue Scale (VAS) -10 Penthrox® Pain Intensity Score -15 -20 -25 -30 -35 -40 1 COFFEY, F
Slide 19: Can reduce patient waiting times to analgesia
Penthrox® Can reduce patient waiting times to analgesia For personal use only USA wait times to analgesia2 80 70 Time (minutes) 60 Average time 50 to analgesia 40 30 minute 30 target 20 Penthrox® assists by being: 10 Self administered 0 Easy to use Virginia Iowa Kansas Nevada Alabama Mississippi
Slide 20: Can reduce resources used in pain management
Penthrox® Can reduce resources used in pain management For personal use only 1TODD, Knox, 2010. Chronic Or Recurrent Pain In The Emergency Department: National Telephone Survey Of Patient Experience; Western Journal of Emergency Medicine. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3027428/ 2 PALME
Slide 21: Can reduce overcrowding in EDs
Penthrox® Can reduce overcrowding in EDs For personal use only Penthrox® has the ability to improve an ED’s medical care as it can: Reduce the time to analgesia Leads to: Increase patient satisfaction levels Treatment of patients outside Reduce the costs to hospitals designated zones Admin
Slide 22: Can reduce the cost of analgesia
Penthrox® Can reduce the cost of analgesia Average costs of an IV Opioid treatment Average costs of a Penthrox® treatment* For personal use only Drug Administration, Staffing & Patient $25 Drug Total Cost: Monitoring, $117 Total Cost: Administrati $1,298 $563* on, $15.75 Adverse Events Costs, $113 S
Slide 23: History of Penthrox: clinical studies and publications
History of Penthrox Clinical studies & publications to present For personal use only Pre-2005 Studies 2005 2010 2017 Obstetrics Burns Pharmacology Colonoscopy Dentistry Prehospital ED Obstetrics Burns Dental Burns Paediatrics ED Pivotal Bone Marrow Analgesia Post-Op Phase III Occupat
Slide 24: History of Penthrox: 75 clinical trials over 30 years
History of Penthrox Clinical studies & publications to present For personal use only patients have been studied in more than 75 clinical trials over 30 years Penthrox is used synominously with methoxyflurane 24
Slide 25: History of Penthrox: patients studied by area
History of Penthrox Clinical studies & publications to present For personal use only 235,861 patients 3% 3% Pharmacology 5% 8% 3% Paediatrics 5% 3% Toxicology Prehospital 8% Safety Emergency Department 3% Wound Care/ Burns Dentistry 22% Military 11% Colonoscopy Radiology Urology 3% Bone Marrow Biops
Slide 26: Future of Penthrox: Value Proposition
Future of Penthrox Value Proposition For personal use only Penthrox can materially improve the throughput Non-narcotic trauma relief, non- of patients7,8 in the ER. It enables better time to addictive, safe.1 analgesia and less medical care and observation compared with opioids. Not a restricted med
Slide 27: Potential global sales for Acute Trauma pain
Future of Penthrox Potential global sales for Acute Trauma pain $2 billion+ For personal use only Peak sales in UK estimated to be Peak sales in Canada could be $50 $72 million per annum* million per annum* Peak sales in Europe estimated to be $250 million per annum* Peak sales in Asia could be $500
Slide 28: Potential global sales for Breakthrough pain
Future of Penthrox Potential global sales for Breakthrough pain $6 billion+ For personal use only Peak sales in USA could be $2 billion per annum* Peak sales in Europe could be $2 billion per annum* Peak sales in Asia could be $1.5 billion per annum* Peak sales in Latin America could be $500 million
Slide 29: Potential global sales for Minor Surgical Procedures
Future of Penthrox Potential global sales for Minor Surgical Procedures $2.3 billion+ For personal use only Peak sales in USA could be $1.3billion per annum* Peak sales in Europe estimated to be $814 million per annum* Peak sales in Asia could be $147 million per annum* Peak sales in Latin America e
Slide 30: Potential global sales for Home Use
Future of Penthrox Potential global sales for Home Use $3 billion+ For personal use only Peak sales in USA could be $900 million per annum* Peak sales in Europe could be $1 billion per annum* Peak sales in Asia could be $620 million per annum* Peak sales in Latin America estimated to be $230 million
Slide 31: Future of Penthrox: USA
Future of Penthrox USA For personal use only MVP submitted a detailed regulatory package to the FDA in January 2016. We received a written response from the FDA detailing it’s opinion on the strengths of our regulatory package and by inference the work required to get Penthrox approved for sale in t
Slide 32: Penthrox clinical program for USA
Future Of Penthrox® Penthrox® clinical program for USA For personal use only 2017 2018 2019 2020 FDA Approval IND Toxicology: Repeat dose and dose ranging - 2 by 28 Day Repeat Dose Healthy Volunteer Trial studies - General validation and Additional Phase III to support assay studies to support exist
Slide 33: Clinical development program
Future of Penthrox Clinical development program For personal use only Additional clinical trials and studies are planned for FY17 (and beyond) which will broaden the indications for use of Penthrox® including: We are developing a program of work to support additional indications for Penthrox worldwi
Slide 34: Clinical development program: Breakthrough Pain and Home Use
Future of Penthrox Clinical development program For personal use only Breakthrough Pain / Repeat Use MVP has begun the clinical program to get Penthrox approved for sale in the USA. As part of that program, several pre-clinical trials will be concluded. These trials will also be used towards the wor
Slide 35: Penthrox Intellectual Property
Penthrox Intellectual Property For personal use only MDI is protecting its future by generating intellectual property from its manufacturing technology and delivery devices. MDI has filed and is managing the following patents and trademarks: • 6 Penthrox Inhaler patents; • 1 manufacturing patent; an
Slide 36: Penthrox Manufacturing
Penthrox Manufacturing For personal use only MDI has invested millions of dollars developing new manufacturing technology, techniques and methods. MDI has: 1. Intellectual property. 2. Global production capacity. 3. Lowest cost to manufacture. 4. Significant competitive advantage. 36
Slide 37: Penthrox Outlook
Penthrox Outlook For personal use only MVP’s ambition is to globalise Penthrox and in doing so make it the main stream analgesic of choice around the world. That process has begun. Over the next 12 months we expect to: 1. Obtain approval to sell Penthrox in more than 20 countries throughout Europe a
Slide 38: Introducing Respiratory Devices
For personal use only Introducing Respiratory Devices 38
Slide 39: MDI Medical Respiratory division
MDI Medical Respiratory division For personal use only MDI has a long history of investing R&D resources to design and improve respiratory devices used to deliver Asthma and COPD medication. In 2011 MDI launched a new range of products using MDI’s Cross Valve TechnologyTM, a patented system of drug
Slide 40: MDI Medical Respiratory division product range
MDI Medical Respiratory division For personal use only MDI offers a range of devices that can be used to help patients manage and take control of their asthma and COPD. • Space Chamber PlusTM anti-static range • Space Chamber PlusTM aerosol spacer • Space ChamberTM re-usable • Compact Spacer Chamber
Slide 41: Respiratory Devices: Existing distribution network
Respiratory Devices Existing distribution network For personal use only Netherlands Switzerland Austria Germany UK Belgium Canada Greece Italy USA Spain Korea Portugal Malaysia Singapore Hong Kong UAE New Zealand Australia 41
Slide 42: Respiratory Division Future
Respiratory Division Future For personal use only MDI respiratory products: • now sell in 20 countries • are ranged in 1600 pharmacies across the USA • have achieved full reimbursement in the USA • are Australia’s leading brand • are delivering strong growth around the world 42
Slide 43: Respiratory Division Future: new products
Respiratory Division Future For personal use only MDI is investing heavily in developing new and innovative products • Anti static spacers • Anti static mask – (1st of its kind) • Collapsible spacer • Economical spacer • Additional patentable devices and technology Two new products are expected to b
Slide 44: Respiratory Devices Intellectual Property
Respiratory Devices Intellectual Property For personal use only MDI is protecting its future by generating intellectual property from its new range of respiratory devices. MDI has filed a number of global patents. MDI has filed international Trade Marks and Registered Designs in more than 20 countri
Slide 45: Respiratory Devices Outlook
Respiratory Devices Outlook For personal use only MVP’s ambition is to globalise the sales of its Respiratory Devices. That process has begun. We already have partners and make sales in more than 18 countries. Over the next 12 months we expect to: 1. Obtain additional partnership deals in the USA an
Slide 46: Introducing MVP Corporate
For personal use only Introducing MVP Corporate 46
Slide 47: Financial Summary of H1FY17
Financial Summary of H1FY17 RECEIPTS FROM CUSTOMERS 34% REVENUE GROSS MARGIN For personal use only 42% 24% RESPIRATORY SALES PENTHROX SALES 142% 14% 47
Slide 48: Financial Summary of H1FY17
Financial Summary of H1FY17 For personal use only 48
Slide 49: Financial Summary of H1FY17
Financial Summary of H1FY17 For personal use only 49
Slide 50: Financial Summary
Financial Summary For personal use only MDI has been profitable every year since listing on the ASX in 2003 and used those profits for registration and additional clinical studies and: • has generated a positive cash flow every year; • pays tax and has paid fully franked dividends; • has received al
Slide 51: MDI Investor Dashboard
MDI Investor Dashboard (ASX: MVP) For personal use only Historical Stock Chart (3yr) Current Stock Price ▲ 0.280 (5.93%) 5.00 2 Mar, 12:00pm Day High 5.080 Day Low 4.810 Open 4.810 Prev. Close 4.720 Avg. Volume 63,642 52 Wk. High 6.850 (3 May 2016) 52 Wk. Low 4.120 (6 Dec 2016) Mkt. Cap 294.34 (Mil)
Slide 52: MDI Corporate Overview
MDI Corporate Overview For personal use only David Williams Dr Harry Oxer Leon Hoare Max Johnston Allan McCallum Phillip Powell Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Chairman Director Director Director Director Director The Managing Director A Medical Co
Slide 53: MDI Global Strategy
MDI Global Strategy New and revised For personal use only materials and process (lowest cost producer and New significant IP) Business Partners Product innovation (worlds best manufacturing processes and delivery devices resulting in significant IP) Clinical trials (Commercial clinical studies to su
Slide 54: Contact Details
Contact Details For personal use only HEAD OFFICE 4 Caribbean Drive Scoresby, Victoria, Australia, 3179 Tel: +61 3 9547 1888 Fax: +61 3 9547 0262 Web: www.medicaldev.com 54
Slide 55: Medical Developments International
For personal use only Medical Developments International
Medical Developments International — Investor Presentation (March 2017) on 6ix